- Home
- NRXS vs THAR Comparison
NRXS vs THAR Comparison
Compare NRXS & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- THAR
- Stock Information
- Founded
- NRXS 2011
- THAR 2017
- Country
- NRXS United States
- THAR United States
- Employees
- NRXS N/A
- THAR N/A
- Industry
- NRXS
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- THAR Health Care
- Exchange
- NRXS Nasdaq
- THAR Nasdaq
- Market Cap
- NRXS 25.8M
- THAR 22.8M
- IPO Year
- NRXS 2023
- THAR 2022
- Fundamental
- Price
- NRXS $2.75
- THAR $3.20
- Analyst Decision
- NRXS Strong Buy
- THAR Strong Buy
- Analyst Count
- NRXS 1
- THAR 1
- Target Price
- NRXS $7.00
- THAR $17.00
- AVG Volume (30 Days)
- NRXS 1.1M
- THAR 2.6M
- Earning Date
- NRXS 11-12-2025
- THAR 11-07-2025
- Dividend Yield
- NRXS N/A
- THAR N/A
- EPS Growth
- NRXS N/A
- THAR N/A
- EPS
- NRXS N/A
- THAR N/A
- Revenue
- NRXS $3,217,531.00
- THAR N/A
- Revenue This Year
- NRXS $62.14
- THAR N/A
- Revenue Next Year
- NRXS $131.87
- THAR N/A
- P/E Ratio
- NRXS N/A
- THAR N/A
- Revenue Growth
- NRXS 41.93
- THAR N/A
- 52 Week Low
- NRXS $1.33
- THAR $0.95
- 52 Week High
- NRXS $6.20
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- NRXS 39.71
- THAR 54.98
- Support Level
- NRXS $2.94
- THAR $2.85
- Resistance Level
- NRXS $3.96
- THAR $3.05
- Average True Range (ATR)
- NRXS 0.34
- THAR 0.49
- MACD
- NRXS -0.11
- THAR 0.02
- Stochastic Oscillator
- NRXS 3.10
- THAR 13.42
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.